166 related articles for article (PubMed ID: 37495516)
21. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
22. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
Int J Neuropsychopharmacol; 2009 Nov; 12(10):1337-54. PubMed ID: 19835659
[TBL] [Abstract][Full Text] [Related]
23. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
Thamm DH; Huelsmeyer MK; Mitzey AM; Qurollo B; Rose BJ; Kurzman ID
Melanoma Res; 2010 Feb; 20(1):35-42. PubMed ID: 19949352
[TBL] [Abstract][Full Text] [Related]
24. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway.
Kajino T; Ren H; Iemura S; Natsume T; Stefansson B; Brautigan DL; Matsumoto K; Ninomiya-Tsuji J
J Biol Chem; 2006 Dec; 281(52):39891-6. PubMed ID: 17079228
[TBL] [Abstract][Full Text] [Related]
25. Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin.
Yu LG; Packman LC; Weldon M; Hamlett J; Rhodes JM
J Biol Chem; 2004 Oct; 279(40):41377-83. PubMed ID: 15247276
[TBL] [Abstract][Full Text] [Related]
26. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
27. Protein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2.
Zeng K; Bastos RN; Barr FA; Gruneberg U
J Cell Biol; 2010 Dec; 191(7):1315-32. PubMed ID: 21187329
[TBL] [Abstract][Full Text] [Related]
28. Inducible Protein Degradation as a Strategy to Identify Phosphoprotein Phosphatase 6 Substrates in RAS-Mutant Colorectal Cancer Cells.
Mariano NC; Rusin SF; Nasa I; Kettenbach AN
Mol Cell Proteomics; 2023 Aug; 22(8):100614. PubMed ID: 37392812
[TBL] [Abstract][Full Text] [Related]
29. IQGAP1 is an oncogenic target in canine melanoma.
Lee BH; Neela PH; Kent MS; Zehnder AM
PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
[TBL] [Abstract][Full Text] [Related]
30. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
Lengyel E; Wang H; Gum R; Simon C; Wang Y; Boyd D
Oncogene; 1997 May; 14(21):2563-73. PubMed ID: 9191056
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
32. Mek1 phosphorylation site mutants activate Raf-1 in NIH 3T3 cells.
Alessandrini A; Greulich H; Huang W; Erikson RL
J Biol Chem; 1996 Dec; 271(49):31612-8. PubMed ID: 8940180
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor effects of perphenazine on canine lymphoma.
Tsuji S; Yabe R; Usui T; Mizuno T; Ohama T; Sato K
J Vet Med Sci; 2016 Sep; 78(8):1293-8. PubMed ID: 27150024
[TBL] [Abstract][Full Text] [Related]
34. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
35. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
37. Study of Molecular Mechanism of the Interaction Between MEK1/2 and Trametinib with Docking and Molecular Dynamic Simulation.
Hashemzadeh S; Ramezani F; Rafii-Tabar H
Interdiscip Sci; 2019 Mar; 11(1):115-124. PubMed ID: 30465279
[TBL] [Abstract][Full Text] [Related]
38. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
39. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
40. MEK inhibitor for gastric cancer with MEK1 gene mutations.
Sogabe S; Togashi Y; Kato H; Kogita A; Mizukami T; Sakamoto Y; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Tomida S; Yasuda T; Takeyama Y; Okuno K; Nishio K
Mol Cancer Ther; 2014 Dec; 13(12):3098-106. PubMed ID: 25253779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
